Following the approval of CAR T cell therapies targeting CD19, the FDA has since approved CAR T cell therapies targeting B-cell maturation antigen (BCMA) for patients with multiple myeloma (MM) (112). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.